NYSEMKT:XXII

22nd Century Group Inc.


22nd Century Group Inc is a US-based plant biotechnology company. It focuses on developing technology that allows the increase or decrease in the level of nicotine and other nicotinic alkaloids in to-bacco plants and levels of canna-bin-oids in can-na-bis plants through genetic engineering and plant breeding. The company is engaged in the research and development of potentially less harmful or modified risk tobacco products and novel to-bacco plant varieties. Other business activities of the company include manufacture, marketing, sales, and distribution of SPECTRUM and VLN proprietary cigarettes, contract manufacturing of third-party branded to-bacco products, research and development of plant varieties of hemp/can-na-bis, the sale of branded proprietary to-baccos, and among others.

22nd Century Group Inc. News

  • 22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
  • 22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
  • Grabar Law Office Investigates Claims on Behalf of Shareholders of 22nd Century Group, Inc. (XXII) as Securities Fraud Class Action Survives Motion to Dismiss
  • 22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown
  • FDA's Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers
  • Grabar Law Office Investigates Claims on Behalf of Shareholders of 22nd Century Group, Inc. (XXII) As Securities Fraud Class Action Survives Motion to Dismiss
  • In a New Audio Interview, Toni Loudenbeck of Traders News Source Interviews John Miller President, 22nd Century Group Inc.
  • 22nd Century Group (XXII) Comments on the Advancement of New Zealand's National Reduced Nicotine Content Law